Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies.

Chinratanalab W, Reddy N, Greer JP, Morgan D, Engelhardt B, Kassim A, Brandt SJ, Jagasia M, Goodman S, Savani BN
Exp Hematol. 2012 40 (6): 431-5

PMID: 22269114 · PMCID: PMC4067702 · DOI:10.1016/j.exphem.2012.01.014

Twenty-six patients with recurrent CD20(+) B-cell lymphoid malignancies received fludarabine, cyclophosphamide, and rituximab-based nonablative conditioning followed by either matched related (n = 18) or unrelated (n = 8) donor allogeneic stem cell transplantation (allo-SCT) between March 2008 and May 2011. Median age of patients at transplantation was 59 years (range, 41-64 years). At diagnosis, 20 (77%) had stage IV disease; 23 (88%) received ≥3 regimens, 14 (54%) received ≥4 regimens, and 4 (15%) had earlier autologous-SCT. All patients had either chemosensitive or stable disease and nine (35%) were in complete remission before transplantation. At the time of analysis, 17 patients were alive with an estimated 2-year overall survival and progression-free survival rate of 63% and nonrelapse mortality of 25%. Grade II to IV acute graft-vs-host-disease occurred in 8 (31%) and chronic graft-vs-host-disease in 6 (23%) patients (extensive, n = 3). Causes of death include progressive disease in four, acute graft-vs-host-disease in two (both after receiving donor lymphocyte infusion for mixed chimerism with residual disease), infection in one, and other (e.g., substance abuse, leukoencephalopathy) in two. Six patients required rehospitalization within 100 days of SCT (mean = 10 days; range, 3-18 days). Our data support fludarabine, cyclophosphamide, and rituximab-based nonablative conditioning allo-SCT in CD20(+) B-cell lymphoid malignancies and it is time to compare this regimen with an alternative reduced-intensity conditioning regimen in B-cell malignancies.

Published by Elsevier Inc.

MeSH Terms (15)

Adult Antigens, CD20 Antineoplastic Combined Chemotherapy Protocols Female Hematopoietic Stem Cell Transplantation Herpesvirus 4, Human Humans Lymphoma, B-Cell Male Middle Aged Patient Readmission Survival Analysis Transplantation Conditioning Treatment Outcome Virus Activation

Connections (3)

This publication is referenced by other Labnodes entities: